BioCentury
ARTICLE | Clinical News

Affiris' Affitope PD03A well tolerated in Phase I to treat early PD

June 22, 2017 11:30 PM UTC

Affiris AG (Vienna, Austria) reported top-line data from a single-blind, placebo-controlled, Austrian Phase I AFF011 trial in 36 patients with early Parkinson’s disease (PD) showing that 15 and 75 µg doses of subcutaneous Affitope PD03A were well tolerated with no treatment-related serious adverse events reported. Local reactions comprised about 59% of adverse events and the majority of local reactions were mild.

Affitope PD03A is an alpha synuclein (SNCA)-mimicking peptide vaccine. Affiris said Affitope PD03A also led a dose-dependent immune response against the SNCA peptide and cross-reactivity against the SNCA-targeted epitope over time...

BCIQ Company Profiles

Affiris AG

BCIQ Target Profiles

Alpha synuclein (SNCA)